Seres Therapeutics Inc (NASDAQ:MCRB) – Analysts at Cantor Fitzgerald boosted their FY2018 earnings per share (EPS) estimates for Seres Therapeutics in a report issued on Sunday. Cantor Fitzgerald analyst W. Tanner now anticipates that the biotechnology company will post earnings of ($2.37) per share for the year, up from their previous forecast of ($2.72).
A number of other research analysts also recently commented on the company. Zacks Investment Research upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. BidaskClub downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, March 9th. Two analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $18.00.
Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Thursday, March 8th. The biotechnology company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.02. The firm had revenue of $3.06 million during the quarter, compared to the consensus estimate of $3.00 million. Seres Therapeutics had a negative return on equity of 103.46% and a negative net margin of 278.44%.
A number of large investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its holdings in Seres Therapeutics by 1.1% during the 2nd quarter. California State Teachers Retirement System now owns 36,280 shares of the biotechnology company’s stock valued at $410,000 after buying an additional 400 shares during the period. Parametric Portfolio Associates LLC raised its holdings in Seres Therapeutics by 2.7% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 21,915 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 580 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Seres Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,270 shares of the biotechnology company’s stock valued at $206,000 after buying an additional 2,410 shares during the period. New York State Common Retirement Fund raised its holdings in Seres Therapeutics by 59.6% during the 2nd quarter. New York State Common Retirement Fund now owns 23,300 shares of the biotechnology company’s stock valued at $263,000 after buying an additional 8,699 shares during the period. Finally, Voya Investment Management LLC purchased a new stake in Seres Therapeutics during the 2nd quarter valued at $114,000. Institutional investors own 81.43% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://stocknewstimes.com/2018/03/14/fy2018-eps-estimates-for-seres-therapeutics-inc-mcrb-lifted-by-cantor-fitzgerald.html.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.